AbbVie (ABBV) sells its products across the world through a number of channels, including wholesalers, distributors, government agencies, healthcare facilities, specialty pharmacies, and independent retailers from AbbVie-owned distribution centers and public warehouses.
In the United States, the company primarily distributes products through independent wholesale distributors.
AbbVie’s key products on the market include Humira, Imbruvica, HCV, Creon, Lupron, Synthroid, Synagis, Androgel, Duodapa, Sevoflurane, and Kaletra. Let’s look at how these products performed in 1Q18.
Humira, AbbVie’s mainstay product, generated sales of $4.7 billion in 1Q18 compared to $4.1 billion in 1Q17, a rise of ~15%. Of this, $3 billion came from US sales, and $1.7 billion came from international sales in 1Q18 compared to $2.7 billion in US sales and $1.4 billion in international sales in 1Q17.
Total Imbruvica sales rose from $551 million in 1Q17 to $762 million in 1Q18. The drug’s US sales rose from $457 million in 1Q17 to $624 million in 1Q18. Its international sales rose almost 50% from $94 million in 1Q17 to $138 million in 1Q18. This rise was due to the continued penetration of Imbruvica as a first-line treatment for chronic lymphocytic leukemia (or CLL) coupled with favorable pricing.
Total HCV sales rose 250% from $263 million in 1Q17 to $919 million in 1Q18. Its US sales rose almost tenfold from $38 million in 1Q17 to $343 million in 1Q18. International HCV sales increased from $225 million in 1Q17 to $576 million in 1Q18. This increase in global HCV sales was due to the launch of Mavyret in certain geographies starting in 2H17.
In the next part of the series, we’ll take a look at the performance of AbbVie’s other key products on the market.